A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms

Status Recruiting

Clinical Trial Summary

TQ05105 is a JAK2 inhibitors and can be used to treat JAK2 target-related diseases. The activation of the JAK/STAT pathway is related to abnormal proliferation, obstruction of apoptosis, and differentiation disorder of leukemia cells which is caused by genetic abnormalities and viral infection.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04339400
Study type	Interventional
Source	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact	Zhijian Xiao, Doctor
Phone	022-23909184
Email	zjxiao@ihcams.ac.cn
Status	Recruiting
Phase	Phase 1
Start date	November 20, 2018
Completion date	June 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04866056` - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.	Phase 1/Phase 2
Recruiting	`NCT05936359` - A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Phase 1
Completed	`NCT02084563` - Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms	Phase 2
Completed	`NCT02125318` - A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders	Phase 2
Not yet recruiting	`NCT06291987` - Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation	Phase 1
Recruiting	`NCT03314974` - Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders	Phase 2
Completed	`NCT03075826` - A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms	Phase 2
Recruiting	`NCT02823210` - Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders
Not yet recruiting	`NCT06313593` - A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms	Phase 1
Active, not recruiting	`NCT05444530` - A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms	Phase 1
Active, not recruiting	`NCT03912064` - A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT	Phase 1
Terminated	`NCT02393248` - Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)	Phase 1/Phase 2
Completed	`NCT02076191` - Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML	Phase 1/Phase 2
Active, not recruiting	`NCT04761770` - Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders	Phase 2
Recruiting	`NCT06034002` - A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms	Phase 1
Completed	`NCT00949364` - Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage	Phase 2
Completed	`NCT00053196` - Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer	Phase 2
Terminated	`NCT01668173` - HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET	Phase 2
Active, not recruiting	`NCT03618485` - Registry of Patients With MPNs in Taiwan